DE60106026D1 - 2-arachidonylglycerol, ein hemmer des tumor nekrose faktors -alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen - Google Patents

2-arachidonylglycerol, ein hemmer des tumor nekrose faktors -alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen

Info

Publication number
DE60106026D1
DE60106026D1 DE60106026T DE60106026T DE60106026D1 DE 60106026 D1 DE60106026 D1 DE 60106026D1 DE 60106026 T DE60106026 T DE 60106026T DE 60106026 T DE60106026 T DE 60106026T DE 60106026 D1 DE60106026 D1 DE 60106026D1
Authority
DE
Germany
Prior art keywords
closed head
arachidonylglycerol
inhibitor
neuroprotector
alfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60106026T
Other languages
English (en)
Other versions
DE60106026T2 (de
Inventor
Raphael Mechoulam
Ruth Gallily
Aviva Breuer
Esther Shohami
David Panikashvili
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of DE60106026D1 publication Critical patent/DE60106026D1/de
Application granted granted Critical
Publication of DE60106026T2 publication Critical patent/DE60106026T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE60106026T 2000-06-23 2001-06-17 2-arachidonylglycerol (2-ag)-ein hemmer des tumor nekrose faktors-alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen Expired - Fee Related DE60106026T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21370500P 2000-06-23 2000-06-23
US213705P 2000-06-23
PCT/IL2001/000551 WO2001097793A2 (en) 2000-06-23 2001-06-17 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury

Publications (2)

Publication Number Publication Date
DE60106026D1 true DE60106026D1 (de) 2004-11-04
DE60106026T2 DE60106026T2 (de) 2006-02-23

Family

ID=22796176

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60106026T Expired - Fee Related DE60106026T2 (de) 2000-06-23 2001-06-17 2-arachidonylglycerol (2-ag)-ein hemmer des tumor nekrose faktors-alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen

Country Status (8)

Country Link
US (1) US6566543B2 (de)
EP (1) EP1292288B1 (de)
JP (1) JP2003535892A (de)
AT (1) ATE277608T1 (de)
AU (1) AU2001266289A1 (de)
DE (1) DE60106026T2 (de)
ES (1) ES2227220T3 (de)
WO (1) WO2001097793A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL216228B1 (pl) * 2001-05-25 2014-03-31 Ares Trading Sa Zastosowanie białka wiążącego IL-18
JP2003048831A (ja) * 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JP2006517194A (ja) 2002-06-06 2006-07-20 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム 骨成長を調節するための方法、組成物および製造物
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
WO2005018632A1 (en) * 2003-08-18 2005-03-03 Btg International Limited Treatment of neurodegenerative conditions
GB2442161B (en) * 2003-08-18 2008-05-21 Btg Int Ltd Triglycerides
GB0319358D0 (en) * 2003-08-18 2003-09-17 Btg Int Ltd Treatment of neurodegenerative conditions
GB2442164B (en) * 2003-08-18 2008-05-21 Btg Int Ltd Treatment of neurodegenerative conditions
JP2006083136A (ja) * 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
KR101578498B1 (ko) 2006-12-28 2015-12-18 산토리 홀딩스 가부시키가이샤 신경 재생제
JP2010540618A (ja) * 2007-10-02 2010-12-24 アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド 幼児の成長および発達を増大するための内在性カンナビノイド
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
US20200069618A1 (en) * 2018-09-04 2020-03-05 John C. Gustin Compositions having an agent and an enhancer thereof, methods of use, and delivery systems

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1247165B (it) * 1991-03-15 1994-12-12 Fidia Spa Uso terapeutico della fosfatidilserina e derivati in patologie degenerative anche associate a disfunsioni immunitarie.
US5456912A (en) * 1993-12-28 1995-10-10 The Regents Of The University Of California Non-methylene interrupted fatty acids as immunomodulators
WO1999051560A1 (en) * 1998-04-03 1999-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Synthetic endogenous cannabinoids analogues and uses thereof

Also Published As

Publication number Publication date
EP1292288B1 (de) 2004-09-29
ES2227220T3 (es) 2005-04-01
WO2001097793A3 (en) 2003-01-09
JP2003535892A (ja) 2003-12-02
ATE277608T1 (de) 2004-10-15
US20020072539A1 (en) 2002-06-13
DE60106026T2 (de) 2006-02-23
AU2001266289A1 (en) 2002-01-02
WO2001097793A2 (en) 2001-12-27
EP1292288A2 (de) 2003-03-19
US6566543B2 (en) 2003-05-20

Similar Documents

Publication Publication Date Title
DE60106026D1 (de) 2-arachidonylglycerol, ein hemmer des tumor nekrose faktors -alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen
TNSN07208A1 (en) 3,5-DISUBTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d] PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
WO2004004661A3 (en) Boroproline compound combination therapy
WO2005063297A3 (en) Melatonin combination therapy for improving sleep quality
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
EP1673078A4 (de) Benzylether- und benzylamino-beta-sekretase-hemmer zur behandlung von alzheimer-krankheit
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
TW200626576A (en) Bicyclic amides as kinase inhibitors
DE60331537D1 (de) Kombinationen zur behandlung von multiplem myelom
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
ATE506059T1 (de) Therapie zur behandlung der überaktiven blase
HK1086011A1 (en) Ccr1 antagonists for the treatment of i.a demyelinating inflammatory disease
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
WO2002079169A8 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
ATE409028T1 (de) Arzneien zur behandlung von nervenerkrankungen
WO2005123651A8 (en) L-2-(α-HYDROXYPENTYL)BENZOATES, THE PREPARATION AND THE USE THEREOF
ATE499933T1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
ATE404192T1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee